Abstract:Introduction Increasing evidence has shown that trefoil factor 3 (TFF3) is increased in expression in various cancers and promotes cancer progression. Elevated TFF3 levels have been reported in lung cancer patients. TFF3, which is expressed in the vast majority of lung adenocarcinomas (ADC), has also been proposed as a novel biomarker to distinguish between lung ADC and squamous-cell carcinoma (SCC). Herein, we investigated the oncogenic functions of TFF3 and explored the potential of therapeutic TFF3 inhibition in NSCLC. Material and methods The function of TFF3 in lung ADC was investigated by either forced or depleted expression of TFF3 in H1299 and H1975 cell lines. Cell functional assays performed include total cell count, PI-Annexin V apoptosis assay, cell cycle analysis, soft agar colony formation, 3Dgrowth in Matrigel, wound healing and transwell migration and invasion assays. A novel small molecule TFF3 inhibitor, AMPC, has been developed in and was used to examine the functional effects of TFF3 inhibition in the lung ADC cells, both as a single agent and in combination with MEK1/2 inhibitors. The paracrine effect of local TFF3 production by lung ADC cells on non-TFF3 expressing lung SCC cells was examined using co-culture assays. Results and discussions The forced expression of TFF3 enhanced cell proliferation and survival, increased anchorage-independent growth, and promoted cell migration and invasion in lung ADC cells. In contrast, the siRNA-mediated depletion of TFF3 expression decreased the oncogenicity of these cells. Consistently, the inhibition of TFF3 by AMPC resulted in markedly decreased cell survival, proliferation, 3D growth and foci formation of lung ADC cells. Expression of the proto-oncogene ARAF was increased by forced expression of TFF3 in lung ADC cells, with consequent increased activation of downstream MEK1/2 and ERK1/2. This TFF3-mediated activation of the MAPK/ERK pathway was required for TFF3-stimulated 3D-growth of lung ADC cells. Moreover, the combination of MEK1/2 inhibitors with AMPC exhibited synergistic inhibitory effects in lung ADC cells. In addition, we demonstrated that the local secretion of TFF3 from lung ADC cells exerts paracrine effects on lung SCC cells, which is relevant in the adenosquamous carcinoma (ASC) subtype of NSCLC. Conclusion TFF3 is a crucial oncogene in NSCLC progression.The therapeutic inhibition of TFF3 alone or in combination with conventional MEK1/2 inhibitors are potential strategies in the treatment of NSCLC.

FFAR2 antagonizes TLR2- and TLR3-induced lung cancer progression via the inhibition of AMPK-TAK1 signaling axis for the activation of NF-κB

Aberrant Fatty Acid Profile and FFAR4 Signaling Confer Endocrine Resistance in Breast Cancer

FFAR4 activation inhibits lung adenocarcinoma via blocking respiratory chain complex assembly associated mitochondrial metabolism

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

Free Fatty Acid Receptors and Cancer: From Nutrition to Pharmacology

FSCN1 Induced PTPRF-dependent Tumor Microenvironment Inflammatory Reprogramming Promotes Lung Adenocarcinoma Progression Via Regulating Macrophagic Glycolysis

“NRF2 Addiction” in Lung Cancer Cells and Its Impact on Cancer Therapy

Synthetic free fatty acid receptor (FFAR) 2 agonist 4-CMTB and FFAR4 agonist GSK13764 inhibit colon cancer cell growth and migration and regulate FFARs expression in in vitro and in vivo models of colorectal cancer

β‐arrestin 2 negatively regulates lung cancer progression by inhibiting the TRAF6 signaling axis for NF-κB activation and autophagy induced by TLR3 and TLR4

Free Fatty Acid Receptor 2, a Candidate Target for Type 1 Diabetes, Induces Cell Apoptosis Through ERK Signaling.

The Second-Generation Tyrosine Kinase Inhibitor Afatinib Inhibits IL-1β Secretion Via Blocking Assembly of NLRP3 Inflammasome Independent of Epidermal Growth Factor Receptor Signaling in Macrophage.

Cancer-associated fibroblasts strengthen cell proliferation and EGFR TKIs resistance through aryl hydrocarbon receptor dependent signals in non-small cell lung cancer

Short-Chain Fatty Acid and FFAR2 Activation - A New Option for Treating Infections?

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells

Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression

TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation

TLR2 Promotes Allergic Airway Inflammation Through JNK Signaling Pathway with Activation of Autophagy

FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion

TLR2-EGR1 signaling axis modulates TGFβ1-induced differentiation of fibroblasts into myofibroblasts in pulmonary fibrosis

PO-001 Therapeutic Inhibition of Trefoil Factor 3(TFF3) Decrease Oncogenic Behaviour in Non-Small Cell Lung Cancer (NSCLC)

Fumarate Hydratase Inhibits Lung Adenocarcinoma Growth And Metastasis Through Regulating Erk Activity